GLP-1 Compounding Crackdown: Your Options Now

On March 3, 2026, the FDA published 30 warning letters targeting telehealth companies selling compounded semaglutide and tirzepatide. Six days later, Hims & Hers struck a deal with Novo Nordisk to stop marketing compounded GLP-1s and sell branded products instead. If you are currently using compounded GLP-1 peptides for weight loss, here is exactly what changed, what is still legal, and where to source them now.

What the FDA Actually Did

The 30 warning letters targeted telehealth platforms -- not compounding pharmacies themselves. The violations were specific:

• Claiming equivalence to FDA-approved drugs (e.g., marketing compounded semaglutide as "the same as" branded products)
• Making unapproved efficacy claims about compounded GLP-1s without clinical data supporting those specific formulations
• Misleading advertising that blurred the line between compounded and FDA-approved medications

The FDA explicitly stated these companies had 15 days to respond or face "legal action without further notice." Several have already removed their compounded GLP-1 listings.

What the FDA did not do: ban compounded semaglutide or tirzepatide outright. The 503A compounding pathway remains intact.

The Hims-Novo Nordisk Deal

The bigger market signal came March 9, when Hims & Hers and Novo Nordisk announced a partnership. Under the deal:

• Hims will offer branded semaglutide on its platform
• Hims will stop advertising compounded GLP-1s (except for documented medical necessity)
• Novo Nordisk dropped its patent lawsuit against Hims

This effectively removes one of the largest telehealth compounded GLP-1 providers from the market. Other telehealth companies are watching closely -- several have already begun negotiating similar branded-product agreements.

Novo Nordisk's Contamination Claims

Novo Nordisk added fuel by reporting that their testing of certain compounded semaglutide products found impurity levels as high as 86%. While this number likely reflects worst-case samples from unregulated sources, it underscores why sourcing from vendors with third-party COA testing matters.

What Is Still Legal (and What Is Not)

Here is the current legal landscape as of April 2026:

Still Legal

• 503A compounding pharmacies preparing semaglutide or tirzepatide with a valid prescription for patients with documented clinical need (allergy to inactive ingredients, specific dosing requirements)
• 503B outsourcing facilities -- multiple court injunctions have prevented the FDA from fully shutting these down, though regulatory pressure continues
• Research-grade peptides from vendors selling for research purposes, which do not fall under FDA drug compounding regulations

No Longer Legal (or Under Pressure)

• Telehealth platforms marketing compounded GLP-1s as equivalent to branded drugs
• Compounding purely for cost savings -- the FDA's position is that lower price alone does not constitute a valid medical reason for compounding when the branded product is available
• Making efficacy claims about compounded formulations that have not been individually tested

The Practical Reality

The semaglutide shortage officially ended in early 2025, which tightened the legal basis for compounding. But 503A pharmacies can still compound when there is a legitimate clinical reason -- and many physicians are writing prescriptions that document specific patient needs.

For tirzepatide, the shortage status is more complex. Multiple court rulings created a patchwork of injunctions that keep compounding access alive in practice, even as the FDA pushes to restrict it.

Where to Source GLP-1 Peptides Now

If your telehealth provider has stopped offering compounded GLP-1s, you have three paths forward.

Option 1: Vetted Peptide Vendors

Research-grade semaglutide and tirzepatide from vendors with third-party COA testing remain available. These are the same compounds, sourced from reputable manufacturers, with purity verification you can check yourself.

Option 2: Compounding Pharmacy with Physician Prescription

Find a 503A compounding pharmacy and a prescribing physician who can document your clinical need. This is the most legally bulletproof path but requires a doctor willing to write the prescription and a pharmacy that has not been spooked by the FDA letters.

Option 3: FDA-Approved Alternatives

Orforglipron just received FDA approval on April 1, making it the easiest legal option -- but it delivers less weight loss than injectable semaglutide or tirzepatide. For maximum efficacy, retatrutide from vetted vendors produces roughly double the weight loss of orforglipron.